Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
March 07, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in vivo KNOXVILLE, TN, March 07,...
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
February 29, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB:...
Global PRMT5 Targeted Therapy Market & Clinical Trials Insights 2024: Innovation and Potential in Oncology and Beyond
February 29, 2024 04:06 ET
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering. ...
Artificial Intelligence / AI in Drug Discovery Research Report 2023 - Global Forecast to 2028: Market to Grow by $4 Billion, at a CAGR of 40.2%
February 27, 2024 03:18 ET
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead Generation, Optimization), Drug Design...
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
February 15, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3...
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
February 14, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it has engaged IR Labs, Inc. (“irlabs”) to...
Generic Oncology Drugs Global Research Report 2023: Market to Reach $33.18 Billion by 2027, Propelled by Rising Cancer Prevalence and Novel Formulations - Long-term Forecasts to 2032
February 08, 2024 09:38 ET
|
Research and Markets
Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "Generic Oncology Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global market for generic oncology...
Europe Constrained Peptide Drugs Market Analysis and Forecast, 2024-2040: Market to Grow by Over $6.5 Billion at a CAGR of 41.55%, Driven by Innovative Pipeline Drugs that Target More than Receptors
February 06, 2024 08:58 ET
|
Research and Markets
Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The "Europe Constrained Peptide Drugs Market: Analysis and Forecast, 2024-2040" report has been added to ResearchAndMarkets.com's offering.The market size...
MPH966 (Alvelestat) Drug Insight with Market Projections to 2032: A Novel Therapy Under Development for Bronchiolitis Obliterans Syndrome (BOS)
January 30, 2024 10:51 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "MPH966 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report offers an in-depth...
TTP399 Drug Insights and Forecasts Across the 7MM, 2023-2032
January 29, 2024 12:31 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "TTP399 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The research outlined in this...